

# Index

Note: Page numbers of chapter titles are in **bold face** type.

**ABNORMAL PHAGOCYTE FUNCTION**, clinical conditions associated with, 27

**Abscess** of the liver, 25

**Actin** dysfunction, and infection, 18

**Agar disc diffusion method**, 74

**Alcoholic liver disease**, 5

**Antibiotic therapy of septic arthritis**, **133-152**

- definitive antibiotic programme, 139
- bacteriostatic and bactericidal drugs, 139
- broad spectrum and narrow spectrum antibiotic drugs, 140
- route of antibiotic administration, 140
- drainage and surveillance, 149
- fungal arthritis, chemotherapy of, 148
- history and physical, 133
- identification of infecting organism, 134
- aspiration and examination of synovial fluid, 134
- clinical indicators for identification of infection, 136

**index of suspicion**, 133

**initial antibiotic selection**, 138

**passage of antibiotics into joints**, 142

**pharmacology of major antibiotic drugs**, 143

- aminoglycosides, 145
- penicillins, 144

**reactions of drugs**, 142

**susceptibility testing**, 74

**tuberculous arthritis**, chemotherapy of, 146

**Antigens**, detection of, 84

**Antimicrobial susceptibility tests**, 75

**Arthritis**, infectious agents of (*see also Infectious arthritis*)

- adenovirus**, 237
- synovial fluid analysis in, 237
- arbovirus**, 226
- atypical mycobacteria**, 214
- fungi**, 216
  - blastomycosis, 218
  - candidiasis, 219
  - coccidioidomycosis, 216
  - sporotrichosis, 218
- gonococci**, 40, 169

**gram-negative bacilli**, 192-210

- characterization of, 201
- predisposing factors, 198
- in intravenous drug users, 198
- in non-intravenous drug users, 198

***Haemophilus influenzae***, 206

**Hepatitis B**, 232

**meningococci**, 177

**mycobacteria**, 211-223, *see* **Tuberculous arthritis**

**rubella**, 228

- vaccination and joint infection, 231

***Salmonella***, 206

***Serratia***, 200

**viruses**, **225-240**, *see* **Viral arthritis**

***Yersinia***, 206

***Aspergillus***, 5

**Assessment of host defences**, 12

**Azurophilic granules**, 15

**BACTERAEMIA**, 4

**Bacteria**, catalase positive, 5

**Bacterial arthritis**, pathological findings in, 34

**Bacterial endocarditis**, 41

**Blastomycosis**, 45, 218

**Brodie's abscess**, 106, 108

**Broth cultures**, 66

**Brucellosis**, 42

**CANDIDA**, 5

**Candidiasis**, 219

**Carcinoma of the lung**, 5

**Cartilage destruction**, mechanism of, 56

**Chediak-Higashi syndrome**, 5, 23, 26

- diagnosis of, 23

**Chemotactic stimuli**, defective response to, 5, 23

**Chronic lymphocytic leukaemia**, associated with hypogammaglobulinaemia, 7

**Coccidioidomycosis**, 44, 216

**Complement**, primary disorders of, associated with infection, 4

**Congenital thymus aplasia**, 8

Counterimmunoelectrophoresis, in detection of antibodies, 87  
 in diagnosis of infectious arthritis, 88

*Cryptococcus neoformans*, demonstration of, 65

**DEFECTS IN HOST DEFENCE MECHANISMS** that predispose to infection, 3-13, see Host defence mechanisms

Dermatitis, 4

DiGeorge syndrome, 8

Disease states associated with defect in host defences, 11

*E. CHOLI*, 5, 197

Eczema, 4

**FASTIDIOUS BACTERIA**, growth of, 66

Felty's syndrome, 4

Fungal arthritis —  
 blastomycosis and, 218  
 chemotherapy of —  
 amphotericin B, 148  
 5-fluorocytosine, 149  
 candidiasis and, 219  
 coccidioidomycosis and, 216  
 identification of infectious agents, 10, 44, 65, 220  
 sporotrichosis and, 218

**GAS CHROMATOGRAPHY**, detection of microbial metabolites, 83  
 diagnosis of infectious arthritis, 88

Glucose-6-phosphate dehydrogenase deficiency, 5

Glutathione peroxide deficiency, in girls, 5

Gonococcal and meningococcal arthritides, 169-180  
 diagnosis, 173-174  
 importance of choice of culture medium, 173  
 gonococcal arthritis, 40, 169  
 clinical spectrum of, 170  
 general characteristics, 170  
 joints and periarthritis lesions, 172  
 miscellaneous features, 173  
 pathogenesis of inflammation, 173  
 skin lesions, 171  
 treatment of, 175  
 antibiotic regimens, 176  
 joint drainage, 176  
 meningococcal arthritis, 177

Gram-negative bacilli, arthritis due to, 197-210, see Arthritis, infectious agents in

Granulomatous disease of childhood, chronic, 25

**HAEMOPHILUS INFLUENZAE**, 7  
 and arthritis, 206  
 in children, 63  
 infections, 10  
 requirements for cultivation, 68

Herpes virus infections, 10

Hexose monophosphate shunt activation, 9

Histoplasmosis, 9  
 differentiation from tuberculosis, 46

Hodgkin's disease, 5, 8, 10

Host defence mechanisms, defects that predispose to infection, 3-13  
 assessment of host defences, 12  
 lymphocytes, 6  
 mononuclear phagocytes, 9  
 neutrophils, 3  
 relevance of specific defects to infection, 10

Hypogammaglobulinaemia, 3  
 X-linked, 6

**IMMUNODEFICIENCY DISEASE** —  
 primary, 6, 7  
 manifestations of, 8

Immunoglobulin, 6

India ink, use with wet mounts of cultures, 65

Infection, predisposition to, due to defects in host defence mechanisms, 3-13, see Host defence mechanisms

Infectious arthritis —  
 aetiology of, in children, 136  
 agents of —  
 adenovirus, 237  
 synovial fluid analysis in, 237  
 arbovirus, 226  
 atypical mycobacteria, 214  
 fungi, 216  
 blastomycosis, 218  
 candidiasis, 219  
 coccidioidomycosis, 216  
 sporotrichosis, 218  
 gonococci, 40, 169  
 gram-negative bacilli, 192-210  
 characterization of, 201  
 predisposing factors, 198

*Haemophilus influenzae*, 206

Hepatitis B, 232

meningococci, 177

mycobacteria, 211-223, see *Tuberculous arthritis*

rubella  
 vaccination and joint infection, 231

*Salmonella*, 206

*Serratia*, 200

viruses, 225-240, see *Viral arthritis*

*Yersinia*, 206

antibiotic therapy for, 133-149, see Antibiotic therapy

joint pathology in, 33-50, *see* Joint pathology  
mechanisms of inflammation in, 51-61, *see* Mechanisms of inflammation  
microbial antigens in, 83-93, *see* Microbial antigen  
microbiology laboratory in diagnosis of, 63-82, *see* Microbiology laboratory  
non-antibiotic aspects of treatment, 153-158  
drainage, 155  
immobilization, 153  
joint positions for optimal functioning, 154  
long-term rehabilitation, 156  
rehabilitation treatment in the acute phase, 154  
nucleographic approaches to diagnosis, 110  
methodology, 112  
radiobiology of radionuclide uptake, 110  
radiology, 95  
infected prostheses, 100  
pre-existing inflammatory arthritis, 95  
pyogenic infections of sacroiliac joints, 102  
tuberculous arthritis, 100  
surgery in, 159-168  
establishing a bacterial diagnosis, 159  
guidelines for surgical intervention, 160  
hinge arthroplasty of the knee, 164  
infections following joint replacement, 162  
delayed infections in prosthetic joints, 163  
early postoperative infection, 162  
natural history of the infected artificial joint, 163  
natural history of the infected prosthesis with loosening, 165  
prevention of cartilage loss, 160  
special case of a paediatric hip, 161  
total joint replacement after infection, 166

Infectious synovitis, immunological factors in, 54

JOINT PATHOLOGY in infectious arthritis, 33-50  
experimental studies, 39  
features seen with specific organisms and situations, 40  
bacterial endocarditis, 41  
brucellosis, 42  
fungal infections, 44  
gonococcal and meningococcal arthritis, 40  
infections superimposed on rheumatoid or other chronic synovitis, 41

syphilis, 46  
tuberculosis, 44  
viral infections, 46  
pathological findings in bacterial arthritis, 34  
cartilage and bone, 39  
synovium, 34  
technique for biopsy and handling of tissue, 33

LANCEFIELD GROUP, testing in identification of streptococci, 69

Leprotomatous leprosy, 9

Leucocytes —  
adherence, 5  
defective function in, 3  
delineation of function of, 10

Lymphocytes —  
primary combined B- and T-cell disorders, 8  
T-cell disorders, 8

Lymphokines, 7

Lymphoma, non-Hodgkins, associated with hypogammaglobulinaemia, 7

MACROPHAGE DYSFUNCTION, patients with, 10

Mechanisms of inflammation in infectious arthritis, 51-61  
changes in synovial fluid chemistry, 57  
synovial fluid findings in septic arthritis, 58

immunological factors in infectious synovitis, 54

mechanisms of cartilage destruction, 56

tissue damage by microbial factors, 51  
bacterial enzymes, 53  
chemotactic factors, 54  
endotoxins, 53  
exotoxins, 51

Meningococcal arthritis, 40

Meningococcal infections, 10

Microbial antigen in infectious arthritis, 83-93  
correlation between antigenaemia and prognosis, 90

counterimmunolectrophoresis in detection of antibodies, 87

detection of antigens, 84  
counterimmunolectrophoresis, 85  
haemagglutination inhibition, 85  
latex agglutination, 84  
radioimmunoassay, 85

detection of microbial metabolites by gas chromatography, 83  
newer diagnostic procedures, 84

newer methods in diagnosis of infectious arthritis, 88

gas chromatography, 88

Microbial antigen in infectious arthritis (cont.)  
 possible role of pneumococcal antigen-antibody complexes in arthritis, 91  
 special problems with serology of gonorrhoea, 87

Microbial killing, disorders of, 25

Microbial-phagocytic interactions, 15-32  
 disorders of chemotaxis, 23  
 disorders of microbial killing, 25  
 metabolic events associated with intracellular killing of bacteria, 21  
 opsonins, 16  
 oxidative metabolism during phagocytosis, 20  
 phagocytic cells in the inflammatory response, 15  
 phagocytosis, 18

Microbiology laboratory in diagnosis of infectious arthritis, 63-82  
 antimicrobial activity of serum and synovial fluid, 78  
 bacterial agents of septic arthritis, 63  
 correlation of bacterial cause with age, 64  
 collection of specimens and transport, 64  
 direct stains and wet mounts of aspirated fluid, 64  
 identification of bacterial and fungal isolates, 69  
 protein binding of antimicrobial agents, 77  
 recovery and identification of infectious agents, 66  
 serological identification of microbial isolates, 73  
 susceptibility testing, 74

Monocytes, proliferation of, diseases associated with, 10

Mononuclear phagocytes, delineation of function of, 10

Mycobacteria, 10, 44, 146

Mycobacterial arthritis, atypical, 214

Myeloperoxidase, 4  
 deficiency of, 5

Multiple myeloma, associated with hypogammaglobulinaemia, 7

NEEDLE SYNOVIAL BIOPSY, 33

*Neisseria gonorrhoeae*, as a cause of arthritis, 40, 63, 169-176, *see also* Gonococcal arthritis  
 requirements for cultivation, 68

Neutropenia, induced by cytotoxic therapy, effect of, 10  
 level of, associated with repeated infections, 4

Neutropenic leukaemia, 4

Neutrophils, 3  
 chemotaxis, defective, patients with, 24

dysfunction, induced by therapeutic measures, 26

Non-antibiotic aspects of treatment in infectious arthritis, 153-158, *see also* Infectious arthritis

Nucleographic approaches to the diagnosis of septic arthritis and osteomyelitis, 110  
 methodology, 112  
 radiobiology of radionuclide uptake, 110

OPONINS, 16  
 coating on bacteria, 3

Opsonization, molecular events in, 17

Osteomyelitis, 25  
 nucleographic approaches to diagnosis, 110  
 radiology in, 103  
 skeletal nucleography in diagnosis of, 117

PARAPROTEINAEMIAS, associated with hypogammaglobulinaemia, 7

Perirectal abscess, 4

Phagocyte function, abnormal, clinical conditions associated with, 27

Phagocytic mononuclear cell, defective function in, 3

Phagocytosis, oxidative metabolism during, 20

Phagolysosome, formation of, 3

Pharyngeal infection, 4

Pneumonia, 4

Pneumococcal infections, 10

*Pneumococcus*, capsular polysaccharide of, 7

*Pneumocystis carini* infections, 10

Polyarthritides, epidemic, 46

Polymorphonuclear leucocytes, primary disorders of, associated with infection, 4  
 leucocyte defects, patients with, 10

Primary combined B-cell and T-cell disorders, 8

Protein calorie malnutrition, 26

*Pseudomonas*, 5, 197

Pyarthrosis, in adults with rheumatoid arthritis, 186  
 radiology as an adjunct to diagnosis in severe clinical settings, 99

Pyogenic arthritis in animal models, 39

Pyogenic infections, following from hypogammaglobulinaemia, 3

RADIOGRAPHIC AND NUCLEOGRAPHIC TECHNIQUES, 95-131  
 newer nucleographic approaches to diagnosis of infections in osseous disease, 127  
 nucleographic approaches to diagnosis of septic arthritis and osteomyelitis, 110

methodology, 112  
radiobiology of radionuclide uptake, 110  
gallium-67-citrate, 112  
properties of radionuclides in bone imaging, 111  
technetium-99m-phosphates, 111  
radiology in osteomyelitis, 103  
bone infection—bone infarction, 109  
chronic osteomyelitis, 105  
osteomyelitis in the diabetic, 109  
tuberculous osteomyelitis, 105  
radiology in septic arthritis, 95  
infected prostheses, 100  
pre-existing inflammatory arthritis, 95  
pyogenic infections of sacroiliac joints, 102  
tuberculous arthritis, 100  
Rheumatoid or other chronic synovitis, infection imposed upon, 41  
Rubella vaccination arthritis, joints affected, 231

**SEPTIC ARTHRITIS, see Infectious arthritis**

*Serratia*, 197  
arthritis, results of drug therapy in, 200  
*S. marcescens*, 5  
Serum antimicrobial activity, 79  
Sickle-cell disease, frequency of osteomyelitis in, 109  
Sinopulmonary infections, recurrent, 7  
Sporotrichosis, 45, 218  
Staphylococcal and other gram-positive coccal arthritides, 181-196  
gram-positive septic arthritis in children, 181  
clinical comments, 183  
gram-positive septic arthritis in adults without arthritic disease, 184  
pyarthrosis in adults with rheumatoid disease, 186  
clinical features, 188  
septic arthritis in adults with rheumatoid disease, 187  
theoretic considerations, 189  
*Staphylococcus aureus*, 4, 5, 63, 69, 181  
*Staphylococcus epidermidis*, 5, 69  
*Streptococcus pneumoniae*, 63, 69  
Surgery in infectious arthritis, 159-168  
guidelines for surgical intervention, 160  
hinge arthroplasty of the knee, 164

infections following joint replacement, 162  
delayed infections in prosthetic joints, 163  
early postoperative infection, 162  
natural history of the infected joint, 163  
total hip replacement after infection, 166

**Synovial fluid** —  
analysis in rubella arthritis, 229  
aspiration and examination, 134  
bacteria isolated in adults with septic arthritis, 198  
chemistry in infectious arthritis, changes in, 57  
optimal culture methods for identification, 135

**Syphilis**, 46

**THAYER-MARTIN MEDIUM**, 68

**Tissue damage by microbial factors**, 51  
bacterial enzymes, 53  
chemotactic factors, 54  
endotoxins, 53  
exotoxins, 51

**Toxoplasma gondii** infections, 10


**Transport of specimens**, 64

**Tuberculosis**, 9, 44  
Tuberculous arthritis, chemotherapy of, 146  
ethambutol, 147  
isoniazid, 147  
rifampicin, 147

**VIRAL ARTHRITIS, 225-240**  
adenovirus arthritis, features of, 237  
adenovirus-7 arthritis, synovial fluid analysis, 237  
arboviral arthritis, 226  
hepatitis-B arthritis, 232  
features of, 232  
selected studies of, joints affected, 233  
serum analysis, 236  
synovial fluid analysis, 234  
pathogenesis of, 225  
rubella arthritis, 228  
features of, 228  
joints affected, 229  
synovial fluid analysis, 230

**Visceral abscesses**, 4

**WHITE BLOOD CELLS**, defective function in, 3



# Index

Note: Page numbers of chapter titles are in **bold face** type.

**ARTHRITIS, see also** Rheumatoid arthritis

childhood. **425-442**

- classification of, 425-426
- conservative orthopaedic measures in, 434-435
- contra-indications for surgery in, 433-434
- general symptomatology, 426-430
- histological examination of, 430
- psychogenic problems in, 430-432
- radiological examination of, 426-429
- surgical possibilities in, 432-433
- surgical requirements for, 435-441

Arthrodesis, 332, 341, 389, 440

Arthropathy, analgesic, 367-368

Arthroplasty, 389, 438-439

- excisional, 396-398, 399
- humeral head replacement, 399
- total replacement, 396, 399-400

Avascular necrosis, of femoral head, **347-373**

- clinical features of, 347-348
- conditions resembling, 366-368
- analgesic arthropathy, 367-368
- pathology of, 351-356
- bone death, 352
- bone dissolution, 366
- osteonecrosis, 353-366
- radiographic features of, 348-351
- treatment of, 368-370

  - high-demand patients, 369
  - low-demand patients, 368-369
  - vascular decompression, 369-370

**BOUTONNIÈRE** deformity, 412

**CHILDHOOD** arthritis, *see* Arthritis, childhood

Chromosome damage, in radiosynoviorthesis, 316-318

Corticosteroids, in induction of osteonecrosis, 364-365

**DEFORMITY**, 267

Drug therapy, for arthritic patients, 256-257

Dysbaric necrosis, 357-361

**ELBOW** —

- assessment of rheumatoid arthritis in, 271-273
- surgery on, **385-402**
- arthroplasty, 396-398
- synovectomy, 393-396

**FEMORAL HEAD**, avascular necrosis of, **347-373**

Foot, rheumatoid, *see* Rheumatoid foot

**GAIT**, analysis of, 280

Gaucher's disease, 363-364

**HALLUX VALGUS**, 463-465

Hand, rheumatoid, *see* Rheumatoid hand

**Hip** —

- articular materials for, 333-336
- metal-on-metal, 333-334
- metal-on-plastic, 335-336
- metal sensitivity, 334-335
- assessment of rheumatoid arthritis in, 277-279, 330-332
- normal joint, 328-330
- replacement, 333-336
- surgery, 332-333, **375-384**
- biomechanical considerations, 327-346
- historical aspects, 375-376
- intraoperative complications, 377
- postoperative sorrows, 377-381
- preoperative preparation, 376
- successes, 381-382

Histological examination, in childhood arthritis, 430

**JOINT** —

- radiographic appearance of, 267-268
- cartilage destruction, 268
- skeletal collapse, 268
- synovial proliferation, 268
- stiffness, 266-267
- synovial, 327-328

**KNEE —**  
 assessment of rheumatoid arthritis in, 279-280  
 chart for, 281-283  
 normal joint, 336-339  
 pathological joint, 339-340  
 replacement of, 343-344  
 rheumatoid, surgical treatment of, 340-342  
 biomechanical considerations, 327-346

**MACINTOSH ARTHROPLASTY, 342**

**ORTHOPAEDIC SURGERY —**  
 aims of, 250-251  
 improvement in appearance, 251  
 improvement in function, 250  
 relief of pain, 250-251  
 assessment of results of, 265-286  
 chart for, 281-283  
 extent of the local disease, 266-268  
 lower limb, 277-280  
 methods for, 268-280  
 the patient, 265-266  
 upper limb, 269-277  
 biomechanical considerations in, 327-346  
 consequences of inaction, 473-474  
 financial aspects of, 472-473  
 cost influences, 472-473  
 cost of non-surgical treatment, 472  
 for childhood arthritis, 425-442  
 contra-indications, 433-434  
 conservative orthopaedic measures, 434-435  
 criteria and classification of, 425-426  
 general symptomatology of, 426-430  
 histological examination in, 430  
 nursing problems, 437  
 possibilities of, 432-433  
 postoperative requirements, 435-436  
 preoperative preparation, 435  
 psychogenic problems, 430-432  
 radiological examination of, 426-429  
 surgical procedures, 437-441  
 technical problems, 436-437  
 future prospects, 469-476  
 epidemiology, 470  
 signs of a problem, 470-472  
 technical problems, 474-475  
 general considerations, 253-258  
 drug therapy, 256-257  
 patient handling and intubation, 256  
 patient's health, 253-254  
 patient's local disease, 254  
 thromboembolism, 257-258  
 wound healing, 254-256  
 medical implications of, 249-263  
 on the hip, 375-384  
 historical aspects of, 375-376  
 intraoperative complications, 377  
 postoperative sorrows, 377-381  
 preoperative preparation, 376  
 successes, 381-382  
 patient assessment in, 251-253  
 evaluation of polyarthritis, 252  
 family response, 253  
 local joint disease, 252  
 patient's mental response, 253  
 patient's requirements, 251  
 prophylactic, 386  
 selection of operative procedures, 386-387  
 technical considerations, 258-261  
 infection of a prosthetic joint, 260-261  
 previous operations, 258-259, 260  
 results required, 259  
 state of skin, 259-260  
 use of a tourniquet, 259  
 technical problems, 474-475  
 upper limb, 385-402

Osteonecrosis, 353-366  
 after fracture of the femoral neck, 356-357  
 alcohol-induced, 365-366  
 corticosteroid-induced, 364-365  
 dysbaric necrosis, 357-361  
 Gaucher's disease and, 363-364  
 idiopathic necrosis of femoral head, 366  
 sickle-cell disease and, 361-363

Osteotomy, 342  
 corrective, 439  
 upper femoral, 332

Outpatients, surgery on, 441

**PAIN, 266**  
 relief of by surgery, 250-251

Patelectomy, 342

Patient, assessment of for surgery, 251-253

Polyarthritis, evaluation of, 252

Prosthetic joint, infection of, 260-261

Pseudoarthrosis, 333

Psychogenic problems, in childhood arthritis, 430-432

**RADIOCOLLOIDS, in treatment of radio-synoviosis —**  
 controlled trials of, 318-321  
 distribution of after injection, 312-314  
 dosimetry, 314-315  
 safety in use of, 314-315  
 selection of, 312-315

Radiological examination, in childhood arthritis, 426-429

**Radiosynoviosis, 311-326**  
 assessment of, 323-324  
 chromosomal damage and, 316-318  
 extra-articular spread of isotope in, 315-316  
 injection techniques, 324

**Radiosynoviorhesis (contd.)**  
radiocolloids for, selection of, 312-315  
selection of patients for, 321-323  
diseases treated, 322-323  
for second injections, 323

**Radiotherapy, intra-articular, side effects of,** 320-321

**Rheumatoid arthritis, see also Orthopaedic surgery**  
chronic, cervical spine in, 443-459  
anatomy of, 443-448  
atlanto-axial subluxation, 450-452  
dorsal column impairment, 455  
pain in, 456  
sub-axial instability, 455-456  
sub-foraminal instability, 443-447  
treatment of, 456-457  
disease staging in, 385-386  
physical signs of, 267  
radiographic appearance of the joints in, 267-268  
symptoms of, 266-267

**Rheumatoid hand, 403-433**  
assessment of, 275-277  
associated sequelae, 413-415  
steroid hand, 414  
vasculitis, 413-414  
deformities in, 407-413  
boutonnierre, 412  
carpometacarpal joint, 407-408  
chain reaction to, 414-415  
digital metacarpophalangeal joint, 408-409  
first metacarpophalangeal joint, 408  
proximal interphalangeal joint, 409  
swan's neck, 412  
synovial involvement in, 407  
tendon involvement in, 412-413  
joint involvement, 406  
articular cartilage, 406  
bone involvement, 406  
ligament involvement, 406  
prophylactic surgery, 417-418  
reconstructive surgery, 420-422  
reparative surgery, 418-420  
intrinsic snap, 419  
repair of ulna drift, 419  
treatment, 419-420  
salvage, 422  
surgical assessment of, 415-422  
contra-indications, 416  
general assessment, 416  
hand assessment, 415-416  
patient selection, 415  
surgical objectives, 416-422  
symptomatic surgery of, 416-417  
synovial involvement, 403-405  
in joints, 403-404  
in tendons, 404-405

**Rheumatoid foot, surgical management of,** 461-467  
ankle joint, 466-467  
cock-up toes and prominent metatarsal heads, 461-462  
hallux valgus, 463-465  
hammer toes and cock-up toes, 462-463  
mid foot and hind foot, 465-466

**SHOULDER —**  
assessment of rheumatoid arthritis in, 270-271  
surgery on, 385-402  
arthrodesis, 399  
arthroplasty, 399-400  
excisional arthroplasty, 399

**Sickle-cell disease, 361-363**

**Skin, effects of rheumatoid arthritis on,** 259-260

**Spine —**  
cervical, in chronic rheumatoid arthritis, 443-459  
anatomy of, 443-448  
atlanto-axial subluxation, 450-452  
dorsal column impairment, 455  
pain in, 456  
sub-axial instability, 455-456  
sub-foraminal instability, 443-447  
treatment of, 456-457  
surgery on, 440-441

**Surgery, see Orthopaedic surgery**

**Swan's neck deformity, 412**

**Synovectomy, 287-309, 332, 341-342,** 437-438  
assessment of, 289-291  
controlled trials of, 292-305  
clinical material, 297-298  
operative and postoperative procedure, 298-299  
results of, 299-301  
dorsal, 392  
flexor, 392-393  
history of, 287-289  
lower extremities, 438  
upper extremities, 437-438  
with excision of radial head, 393-396

**Synovial joints, 327-328**

**Synovitis —**  
acute, 404, 404-405  
fibrosing, 404, 405  
nodular, 405  
proliferating, 404, 405

**TEMPOROMANDIBULAR JOINT, surgery on,** 440-441

**Tenotomy, 440**

**Thromboembolism, from orthopaedic surgery,** 257-258

**Tourniquet, use of, 259**

**VASCULITIS**, 413-414

**WOUND HEALING**, in arthritic patients, 254-256

Wrist—

assessment of rheumatoid arthritis in, 273-274

surgery on, 385-402

arthrodesis, 389

arthroplasty, 389

excision of the lower end of the ulna with synovectomy, 388-389

operative procedures, 392-393

tendon sheath involvement, 392-393





# Index

Note: Page numbers of article titles are in **bold face** type.

**ABNORMAL** immunoregulation, in rheumatoid arthritis, 577-581

Abnormal T-B cell interaction, causing a lupus erythematosus-like syndrome, **587-602**

Abortion, clonal, 540-542

Alloantigens, differentiation, as models of self-tolerance, 542-543

Animal GVHR, 588-595

Ankylosing spondylitis and immune complexes, 630

Antibody—

- antilymphocyte—
  - and disease activity, 650-652
  - and neuropsychiatric disease, 652-655
- cellular interactions in production of, **481-497**
- lymphocytotoxic, 644-648
- non-cytotoxic antilymphocyte, 648-650
- production, cellular interactions in, **481-497**

responses—

- control of the major histocompatibility complex, 492-495
- role of the MHC in, 492-495
- suppression of, and tolerance, 489-492
- T helper cell factors, and T-cell-macrophage-B-cell interactions, 486-489

Antigen processing, role of the macrophage in, 505-506

Antigen reprocessing by macrophages, 544-545

Antilymphocyte antibodies—

- and disease activity, 650-652
- and neuropsychiatric disease, 652-655
- non-cytotoxic, 648-650

Antilymphocyte/antineuronal autoantibodies, pathogenetic implications of, 655-656

Arthritis, rheumatoid, 634-636

- abnormal immunoregulation in, 577-580
- and autoimmunity and infection, **565-586**

exemplifying the interaction of immunocompetent cells and chronic inflammation, **517-537**

and immune complexes, 627-630

matrix degradation in, 519

viral models for the pathogenesis of, 569-577

Autoantibodies—

- antilymphocyte/antineuronal, pathogenetic implications of, 655-656
- to double-stranded DNA in GVH F<sub>1</sub> mice, **591**
- formation of, 597
- to lymphocyte membrane antigens, 643-659
- to nuclear antigens in GVH F<sub>1</sub> mice, **590-591**

Autoantibody formation during GVHR—pathological conditions caused by, 589-592

principle of, 588-589

Autoimmune complex glomerulonephritis, and serum sickness syndrome of GVH F<sub>1</sub> animals, 591-592

Autoimmunity—

- and infection and rheumatoid arthritis, **565-586**
- mechanisms of, 545-546
- and self-tolerance, new ideas about, **539-548**

**BACTERIA, intracellular, and viruses, cell-mediated immunity to, 549-563**

B-cell—

- and T-cell co-operation, hapten-carrier effects in, 482-483
- macrophage-T-cell interactions in the antibody response: T helper cell factors, 486-489

Biological properties of immune complexes, 617-618

- detection methods based on, 622-627

Biological roles of the complement pathway, **605-606**

C2 deficiency, 608–613  
and disease, 611–613  
and HLA linkage, 608–611  
inherited deficiency of, 603–615

Cell-derived chemotactic factors, 504–505

Cell growth, and prostaglandins and cyclic AMP, 530–533

Cell interactions—  
in the humoral response,  
in the induction of T helper cells, 485–486  
in vitro technology for examining, 484–485

Cell-mediated immunity, 549–563  
nature of, 549–550

Cells—  
of the rheumatoid synovium, 519–522  
synovial, collagenase- and prostaglandin-producing, 522–526

Cellular interactions—  
in antibody production, 481–497  
in the humoral immune response, 481–485

Chemotactic factors—  
cell-derived, 504–505  
complement derived, 502–503

Chronic graft-versus-host reaction, 587–602

Chronic inflammation, and immunocompetent cells, 517–537

Clonal abortion, 540–542

Collagenase-producing synovial cells, 522–526

Complement—  
-derived chemotactic factors, 502–503  
genetics, 606–607  
pathway, 603–607

Complement activation and immune complexes, in rheumatic diseases, 632–636

Connective tissue destruction, mediators in, 527–528

Constituent proteins, 603–605

Coombs'-positive haemolytic anaemia of GVH F<sub>1</sub> mice, 589–590

Cyclic AMP, and prostaglandins and cell growth, 530–533

Cytotoxic T cells, a cautionary note concerning, 545

DEFICIENCY, of C2, 608–613

Detection methods—  
based on biological properties of immune complexes, 622–627  
based on physical properties of immune complexes, 620–622  
for soluble immune complexes, 620–627

Differentiation alloantigens, as models of self-tolerance, 542–543

Disease activity and antilymphocyte antibodies, 650–652

Disease and C2 deficiency, 611–613

Distribution, population 608

EFFECTS and fate of immune complexes, 618–620

FATE and effects of immune complexes, 618–620

Formation of autoantibodies, 597

GENETICS, of complement, 606–607

GVH F<sub>1</sub> animals—  
autoimmune complex glomerulonephritis and serum sickness syndrome of, 591–592  
other pathological symptoms of, 592–593  
serum sickness syndrome of, 592

GVH F<sub>1</sub> mice—  
autoantibodies to double-stranded DNA in, 591  
autoantibodies to nuclear antigens in, 590–591  
Coombs'-positive haemolytic anaemia of, 589–590

GVHR—  
animal, 588–595  
lymphomagenesis during, 593–595  
pathological conditions caused by autoantibody formation during, 589–592  
principle of autoantibody formation during, 588–589

HAPten-carrier effects, in T- and B-cell cooperation, 482–483

HLA linkage—  
and C2 deficiency, 608–611  
and rheumatic disease associations, 603–615

Humoral immune response, cellular interactions in, 481–485

Humoral response, cell interactions involved in, and in vitro technology, 484–485

Hydrolases, 507

IMMUNE complexes—  
and ankylosing spondylitis, 630  
biological properties of, 617–618  
and complement activation in rheumatic diseases, 632–636  
detection methods based on biological properties of, 622–627  
detection methods based on physical properties of, 620–622  
fate and effects of, 618–620  
relevance in rheumatic diseases, 627–632  
and rheumatoid arthritis, 627–630  
and rheumatic diseases, 617–642  
soluble, methods for the detection of, 620–627

**Immune complexes (contd.)**  
 and systemic lupus erythematosus, 631-632

**Immune response, humoral, cellular interactions in**, 481-485

**Immunity—**  
 cell-mediated, 549-563  
 nature of, 549-550

**Immunocompetent cells, and chronic inflammation**, 517-537

**Immunological surveillance, and specificity for the major histocompatibility complex**, 552-554

**Immunoregulation, abnormal, in rheumatoid arthritis**, 577-581

**Immunoregulatory products**, 508

**Infection, and autoimmunity and rheumatoid arthritis**, 565-586

**Inherited deficiency of C2**, 603-615

**Interactions, cellular—**  
 in antibody production, 481-497  
 in the humoral immune response, 481-485

**Intracellular bacteria and viruses, cell-mediated immunity to**, 549-563

**In vitro technology, and cell interactions in the humoral response**, 484-485

**LUPUS erythematosus-like syndrome, caused by abnormal T-B cell interaction**, 587-602

**Lymphocyte membrane antigens, autoantibodies to**, 643-659

**Lymphocytes and monocytes, interactions between**, 528-530

**Lymphocytotoxic antibody**, 644-648

**Lymphomagenesis**, 597-599  
 during GVHR, 593-595

**MACROPHAGE—**  
 mechanisms of accumulation and activation, 502-505  
 role in antigen processing, 505-506  
 role in antigen reprocessing, 544-545  
 role in rheumatic diseases, 499-515  
 as a secretory cell, 506-508  
 -T-cell-B-cell interactions in the antibody response: T helper cell factors, 486-489  
 -T-cell interactions, 485-486

**Major histocompatibility complex—**  
 antibody responses under the control of, 492-495  
 role in T-B co-operation, 483-484  
 specificity for, and immunological surveillance, 552-554

**Matrix degradation, in rheumatoid arthritis**, 519

**Mechanisms of autoimmunity**, 545-546

**MHC—**  
 components, recognition of, 555-558  
 role in antibody responses, 492-495  
 structures, self, T-cell reactions towards, 595-597

**Model—**  
 for macrophage role in rheumatic diseases, 508-510  
 for T-cell recognition, 558-559

**Monocytes and lymphocytes, interactions between**, 528-530

**Mononuclear phagocyte system**, 500-502

**NEUROPSYCHIATRIC disease and anti-lymphocyte antibodies**, 652-655

**Non-cytotoxic antilymphocyte antibodies**, 648-650

**PATHOGENESIS—**  
 of rheumatoid arthritis, viral models for, 569-577  
 T-cell reactions towards self MHC structures and, 597-599

**Pathogenetic implications—**  
 of antilymphocyte/antineuronal autoantibodies, 655-656  
 of autoantibodies to lymphocyte membrane antigens, 643-659

**Pathological conditions, caused by autoantibody formation during GVHR**, 589-592

**Pathological symptoms, other, of GVH F<sub>1</sub> animals**, 592-593

**Physical properties of immune complexes, detection methods based on**, 620-622

**Population distribution**, 608

**Programmed self-tolerance**, 543-544

**Prospectus, role of macrophages in the rheumatic diseases and**, 510-511

**Prostaglandin-producing synovial cells**, 522-526

**Prostaglandins**, 507-508  
 and cyclic AMP and cell growth, 530-533

**Proteins, constituent**, 603-605

**RECOGNITION of MHC components**, 555-558

**Rheumatic disease associations, and HLA linkage**, 603-615

**Rheumatic diseases—**  
 complement activation and immune complexes in, 632-636  
 conceptual model for the role of macrophages in, 508-510  
 and immune complexes, 617-642  
 role of macrophages in, 499-515

**Rheumatoid arthritis**, 634-636  
 abnormal immunoregulation in, 577-581  
 and autoimmunity and infection, 565-586

Rheumatoid arthritis (*contd.*)  
 exemplifying the interaction of immunocompetent cells and chronic inflammation, 517-537  
 and immune complexes, 627-630  
 matrix degradation in, 519  
 viral models for the pathogenesis of, 569-577  
 Rheumatoid synovium, cells of, 519-522

SELF MHC structures—  
 T-cell reactions towards, 595-597  
 and pathogenesis of diseases, 597-599

Self-tolerance—  
 and autoimmunity, new ideas about, 539-548  
 differentiation alloantigens as models of, 542-543  
 programmed, 543-544  
 Sensitizing drugs, causing diseases, 597-599  
 Serum sickness syndrome, and autoimmune complex glomerulonephritis of GVH  $F_1$  animals, 591-592  
 Soluble immune complexes, methods for the detection of, 620-627  
 Specificity for virus, 551-552  
 Spondylitis, ankylosing, and immune complexes, 630  
 Suppressor T cells, an SOS system, 542  
 Synovial cells, collagenase- and prostaglandin-producing, 522-526  
 Systemic lupus erythematosus, 633-634  
 and immune complexes, 631-632

T- and B-cell co-operation—  
 hapten-carrier effects in, 482-483  
 role of the major histocompatibility complex in, 483-484

T-B cell interaction, abnormal, causing a lupus erythematosus-like syndrome, 587-602

T-cell—  
 and B-cell co-operation, hapten-carrier effects in, 482-483  
 cytotoxic, a cautionary note concerning, 545  
 -macrophage-B-cell interactions in the antibody response: T helper cell factors, 486-489  
 -macrophage interactions, 485-486  
 and pathogenesis of diseases, 597-599  
 reactions, towards self MHC structures, 595-597  
 receptors, 554-559  
 recognition, models for, 558-559  
 specificity, the problem of, 550-554  
 suppressor, an SOS system, 542

T helper cell factors, and T-cell-macrophage-B-cell interactions in the antibody response, 486-489

T helper cells—  
 cell interactions in the induction of, 485-486  
 T-T-cell interactions in the induction of, 486

Tolerance—  
 self—  
 and autoimmunity, new ideas concerning, 539-548  
 differentiation alloantigens as models of, 542-543  
 programmed, 543-544  
 suppression of antibody responses and, 489-492  
 T-T-cell interactions, in the induction of T helper cells, 486

VIRAL infections, causing diseases, 597-599  
 Viral models, for the pathogenesis of rheumatoid arthritis, 569-577  
 Virus, specificity for, 551-552  
 Viruses and intracellular bacteria, cell-mediated immunity to, 549-563

DEX

carrier

erning,

the an-

actors,

9

ictures,

cell-  
in the

on of,

on of,

concer-

models of,

s and,

on of T

7-599

ysis of

, cell-

3